Chest
Clinical InvestigationsTUBERCULOSISOutcomes of Patients With Multidrug-Resistant Pulmonary Tuberculosis Treated With Ofloxacin/Levofloxacin-Containing Regimens
Section snippets
Data Collection
The inpatient and outpatient medical records of 79 patients with MDR-TB were reviewed. These patients had been admitted to Grantham Hospital, a tertiary referral center for tuberculosis (TB), from chest clinics under the administration of the Department of Health in Hong Kong between February 1990 and June 1997. All 79 patients were seronegative for the HIV antibody by the enzyme-linked immunosorbent assay. M tuberculosis was identified by sputum culture or by both smear and culture. In vitro
Patients Excluded
Sixteen patients were excluded because they received treatment for< 6 months. Two patients left against medical advice and did not receive any chemotherapy. Another two patients succumbed before chemotherapy could be initiated; they had severe COPD and carcinomatosis. Three patients died of diseases other than TB: the first was a 72-year-old man who died of chronic renal failure after 5 months of drug treatment. Sputum smear and culture for AFB had converted from positive to negative after 1
Discussion
In this community, the initial MDR-TB prevalence rates ranged from 0.4 to 0.7%, and the combined MDR-TB prevalence rates ranged from 0.9 to 1.0% in the study period (unpublished data, Department of Health, Hong Kong). The demographic and clinical characteristics of MDR-TB patients in our analyzed cohort were similar to other series, with a predominance of male patients.19, 2021, 2223, 24 Approximately 40% of our patients did not receive any previous antituberculosis drugs. Our high initial
ACKNOWLEDGMENT
The authors thank Professor David Schlossberg for reviewing the manuscript.
References (32)
- et al.
Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis
Chest
(1992) A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin
Tubercle Lung Dis
(1992)- et al.
Drug-resistant tuberculosis: laboratory issues: World Health Organization recommendations
Tubercle Lung Dis
(1994) - et al.
Retreatment tuberculosis cases: factors associated with drug resistance and adverse outcomes
Chest
(1997) - et al.
Emergence of fluoroquinolone-resistant tuberculosis in New York City
Lancet
(1995) In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL 8280)
Am Rev Respir Dis
(1985)- et al.
In-vitro susceptibility of mycobacteria to ciprofloxacin
J Antimicrob Chemother
(1985) - et al.
Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria
Am J Med
(1987) - et al.
In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis
J Antimicrob Chemother
(1987) - et al.
In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria
Eur J Clin Microbiol
(1987)
Therapeutic effect of a new antibacterial substance ofloxacin (DL 8280) on pulmonary tuberculosis
Am Rev Respir Dis
In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis
J Antimicrob Chemother
Ofloxacin-based chemotherapy in multiply drug-resistant pulmonary tuberculosis
Drugs
Randomized controlled trial of a drug regimen which includes ciprofloxacin in the treatment of pulmonary tuberculosis
Clin Infect Dis
Treatment of multidrug-resistant tuberculosis
N Engl J Med
Guidelines for the management of drug-resistant tuberculosis WHO/TB/96.210 (rev 1)
Cited by (0)
Presented in abstract form at the 1999 Annual Congress of the European Respiratory Society at Madrid, Spain.